353 related articles for article (PubMed ID: 27329132)
1. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
[TBL] [Abstract][Full Text] [Related]
2. Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study.
Tsutsumi I; Kunisawa S; Yoshida C; Seki M; Komeno T; Fushimi K; Morita S; Imanaka Y
Int J Clin Oncol; 2019 Nov; 24(11):1449-1458. PubMed ID: 31300904
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole Concentrations in Cerebrospinal Fluid During Prophylactic Use in Children with Acute Myelogenous Leukemia.
Kobayashi R; Sano H; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
Pediatr Infect Dis J; 2016 Mar; 35(3):297-8. PubMed ID: 26650112
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of prophylaxis with high and low doses of voriconazole in children with malignancy.
L Kandaurava S; S Baslyk K; A Migas A; V Hill A; I Bydanov O; A Mishkova V; V Aleinikova O
Curr Med Mycol; 2020 Dec; 6(4):27-34. PubMed ID: 34195457
[TBL] [Abstract][Full Text] [Related]
5. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
Yeh TC; Liu HC; Hou JY; Chen KH; Huang TH; Chang CY; Liang DC
Cancer; 2014 Apr; 120(8):1255-62. PubMed ID: 24415457
[TBL] [Abstract][Full Text] [Related]
6. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients.
Imataki O; Yamaguchi K; Uemura M; Fukuoka N
Transpl Infect Dis; 2018 Aug; 20(4):e12886. PubMed ID: 29570914
[TBL] [Abstract][Full Text] [Related]
9. Management of Invasive Fungal Infections in Pediatric Acute Leukemia and the Appropriate Time for Restarting Chemotherapy.
Tüfekçi Ö; Yılmaz Bengoa Ş; Demir Yenigürbüz F; Şimşek E; Karapınar TH; İrken G; Ören H
Turk J Haematol; 2015 Dec; 32(4):329-37. PubMed ID: 25913290
[TBL] [Abstract][Full Text] [Related]
10. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
11. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes.
Nganthavee V; Phutthasakda W; Atipas K; Tanpong S; Pungprasert T; Dhirachaikulpanich D; Krithin S; Tanglitanon S; Jutidamronphang W; Owattanapanich W; Chayakulkeeree M; Phikulsod P
Support Care Cancer; 2019 Sep; 27(9):3613-3622. PubMed ID: 31165931
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
[TBL] [Abstract][Full Text] [Related]
13. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
14. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
[TBL] [Abstract][Full Text] [Related]
15. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
[TBL] [Abstract][Full Text] [Related]
16. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
17. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole prophylaxis in leukemic patients: A retrospective single-center study.
Bui V; Walker SA; Elligsen M; Vyas A; Kiss A; Palmay L
J Oncol Pharm Pract; 2020 Jun; 26(4):873-881. PubMed ID: 31566111
[TBL] [Abstract][Full Text] [Related]
19. Impact of the D-index deduced from duration and intensity of neutropenia following chemotherapy on the risk of invasive fungal infection in pediatric acute myeloid leukemia.
Sano H; Kobayashi R; Suzuki D; Hori D; Kishimoto K; Kobayashi K
Int J Hematol; 2018 Jul; 108(1):85-90. PubMed ID: 29564800
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of liposomal amphotericin against febrile neutropenia in pediatric patients receiving prophylactic voriconazole.
Kobayashi R; Matsushima S; Hori D; Sano H; Suzuki D; Kishimoto K; Nakano T; Yanagi M; Kodama K; Kobayashi K
Pediatr Int; 2021 May; 63(5):550-555. PubMed ID: 32869416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
